858 Therapeutics
Dr. Samie Jaffrey is the Greenberg-Starr Professor in the Department of Pharmacology at the Weill Cornell Medical College.
Dr. Jaffrey’s work has fundamentally advanced our understanding of RNA biology and gene regulation. Most recently, he helped to launch the field of "epitranscriptomics", which has revealed that mRNA and long noncoding RNAs are regulated by nucleotide modifications that impact their fate and function in cells. Dr. Jaffrey’s transcriptome-wide mapping of N6-methyladenosine (m6A) in 2012 revealed that m6A is a pervasive modification in the transcriptome, thereby identifying this modification as a fundamentally novel form of post-transcriptional mRNA regulation. Since this seminal study, Dr. Jaffrey mapped dimethyladenosine (m6Am) and established functions of m6A and m6Am as well as m6A and m6Am reader, writer, and eraser proteins. The mapping methods developed by Dr. Jaffrey have been the essential tool in epitranscriptomics, and have transformed our understanding of gene regulation in normal and disease states.
Dr. Jaffrey is an elected member of the American Society for Clinical Investigation, and the recipient of the 2017 John J. Abel Award in Pharmacology, the 2014 American Society for Biochemistry and Molecular Biology, the Young Investigator Award Klingenstein Neuroscience Award, Irma T. Hirschl Scholar Award, the McKnight Foundation Technology Development Award, NIH EUREKA Award, the NIH Director’s Transformative R01 Award, and the 2013 Blavatnik Award for Young Scientists.
This person is not in the org chart
This person is not in any offices
858 Therapeutics
858 Therapeutics is a biotechnology and drug discovery company developing a portfolio of small molecule drugs that act on novel therapeutic targets in oncology, including proteins that regulate RNA and the innate immune response.